Therapeutic drugs and drug delivery systems targeting stromal cells for cancer therapy: a review

References

• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437.
   PubMed Web of Science ®Google Scholar
• Roma-Rodrigues C, Mendes R, Baptista PV, et al. Targeting Tumor Microenvironment for Cancer Therapy. Int J Mol Sci. 2019;20(4):pii:E840.
   Web of Science ®Google Scholar
• Lederle W, Hartenstein B, Meides A, et al. MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis. 2010;31(7):1175–1184.
   PubMed Web of Science ®Google Scholar
• Gross S, Rahal R, Stransky N, et al. Targeting cancer with kinase inhibitors. J Clin Invest. 2015;125(5):1780–1789.
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–287.
   PubMed Web of Science ®Google Scholar
• Tian YH, Li SP, Song J, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35(7):2383–2390.
   PubMed Web of Science ®Google Scholar
• Li L, Yang WW, Xu DG. Stimuli-responsive nanoscale drug delivery systems for cancer therapy. J Drug Targeting. 2019;27(4):423–433.
   PubMed Web of Science ®Google Scholar
• AjazuddinSaraf S. Applications of novel drug delivery system for herbal formulations. Fitoterapia. 2010;81(7):680–689.
   PubMed Web of Science ®Google Scholar
• Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Targeting. 2016;24(3):179–191.
   PubMed Web of Science ®Google Scholar
• Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346–354.
   PubMed Web of Science ®Google Scholar
• Ungefroren H, Sebens S, Seidl D, et al. Interaction of tumor cells with the microenvironment. Cell Commun Signal. 2011;9(1):18.
   PubMedGoogle Scholar
• Yu Y, Xiao CH, Tan LD, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. Br J Cancer. 2014;110(3):724–732.
   PubMed Web of Science ®Google Scholar
• Anton K, Glod J. Targeting the tumor stroma in cancer therapy. Curr Pharm Biotechno. 2009;10(2):185–191.
   PubMed Web of Science ®Google Scholar
• Chen XM, Song EW. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99–115.
   PubMed Web of Science ®Google Scholar
• Xouri G, Christian S. Origin and function of tumor stroma fibroblasts. Semin Cell Dev Biol. 2010;21(1):40–46.
   PubMed Web of Science ®Google Scholar
• Egeblad M, Littlepage LE, Werb Z. The fibroblastic coconspirator in cancer progression. Cold Spring Harbor Symp Quant Biol. 2005;70(1):383–388.
   PubMedGoogle Scholar
• Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci. 2010;15(1):166–179. Jan 1
   Google Scholar
• Yoshida GJ, Azuma A, Miura Y, et al. Activated fibroblast program orchestrates tumor initiation and progression; molecular mechanisms and the associated therapeutic strategies. Int J Mol Sci. 2019;20(9):pii:E2256.
   Web of Science ®Google Scholar
• Franz M, Grun K, Betge S, et al. Lung tissue remodelling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and changes in extracellular matrix and fibrosis associated gene expression. Oncotarget. 2016;7(49):81241–81254.
   PubMedGoogle Scholar
• Scott AM, Wiseman G, Welt S, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9(5):1639–1647.
   PubMed Web of Science ®Google Scholar
• Lee HO, Mullins SR, Franco-Barraza J, et al. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer. 2011;11(1):245.
   PubMedGoogle Scholar
• Cao YH. Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. Trends Mol Med. 2013;19(8):460–473.
   PubMed Web of Science ®Google Scholar
• Pietras K, Sjoblom T, Rubin K, et al. PDGF receptors as cancer drug targets. Cancer Cell. 2003;3(5):439–443.
   PubMed Web of Science ®Google Scholar
• Cai J, Du SX, Wang H, et al. Tenascin-C induces migration and invasion through JNK/c-Jun signalling in pancreatic cancer. Oncotarget. 2017;8(43):74406–74422.
   PubMedGoogle Scholar
• Chen B, Dai W, Mei D, et al. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system. J Control Release. 2016;241:68–80.
   PubMed Web of Science ®Google Scholar
• Kakinuma Y, Saito F, Osawa S, et al. A mechanism of impaired mobility of oligodendrocyte progenitor cells by tenascin C through modification of wnt signaling. FEBS Letters. 2004;568(1-3):60–64.
   PubMed Web of Science ®Google Scholar
• Mischke D, Korge BP, Marenholz I, et al. Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex (“epidermal differentiation complex”) on human chromosome 1q21. J invest dermatol. 1996;106(5):989–992.
   PubMed Web of Science ®Google Scholar
• Schafer BW, Wicki R, Engelkamp D, et al. Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics. 1995;25(3):638–643.
   PubMed Web of Science ®Google Scholar
• Sherbet GV. Metastasis promoter S100A4 is a potentially valuable molecular target for cancer therapy. Cancer Letters. 2009;280(1):15–30.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022.
   PubMed Web of Science ®Google Scholar
• Araos P, Prado C, Lozano M, et al. Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation. J Hypertens. 2019;37(7):1482–1492.
   PubMed Web of Science ®Google Scholar
• Li W, Song XJ, Yu HJ, et al. Dendritic cell-based cancer immunotherapy for pancreatic cancer. Arab J Gastroenterol. 2018;19(1):1–6.
   PubMed Web of Science ®Google Scholar
• Smith HA, Kang YB. The metastasis-promoting roles of tumor-associated immune cells. J Mol Med. 2013;91(4):411–429.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207–212.
   PubMed Web of Science ®Google Scholar
• Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229(1):12–26.
   PubMed Web of Science ®Google Scholar
• Torres Andon F, Alonso MJ. Nanomedicine and cancer immunotherapy – targeting immunosuppressive cells. J Drug Targeting. 2015;23(7–8):656–671.
   PubMed Web of Science ®Google Scholar
• Castellaro AM, Rodriguez-Baili MC, Di Tada CE, et al. Tumor-associated macrophages induce endocrine therapy resistance in er plus breast cancer cells. Cancers. 2019;11(2):189.
   Web of Science ®Google Scholar
• Zhou S, Zhang T, Peng B, et al. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity. Int J Pharm. 2017;523(1):203–216.
   PubMed Web of Science ®Google Scholar
• Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18(5):349–355.
   PubMed Web of Science ®Google Scholar
• Aldawsari HM, Gorain B, Alhakamy NA, et al. Role of therapeutic agents on repolarisation of tumour-associated macrophage to halt lung cancer progression. J Drug Targeting. 2020;28(2):166–175.
   PubMed Web of Science ®Google Scholar
• Schmieder A, Michel J, Schonhaar K, et al. Differentiation and gene expression profile of tumor-associated macrophages. Semin Cancer Biol. 2012;22(4):289–297.
   PubMed Web of Science ®Google Scholar
• East L, Isacke CM. The mannose receptor family. Biochim Biophys Acta. 2002;1572(2–3):364–386.
   PubMed Web of Science ®Google Scholar
• Movahedi K, Schoonooghe S, Laoui D, et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 2012;72(16):4165–4177.
   PubMed Web of Science ®Google Scholar
• Maniecki MB, Etzerodt A, Ulhoi BP, et al. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer. 2012;131(10):2320–2331.
   PubMed Web of Science ®Google Scholar
• Cheng ZG, Zhang DH, Gong BC, et al. CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer. Oncotarget. 2017;8(50):87244–87262.
   PubMedGoogle Scholar
• Castelli C, Rivoltini L, Rodolfo M, et al. Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. Cancer Immunol Immunother. 2015;64(1):83–89.
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 Expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–856.
   PubMed Web of Science ®Google Scholar
• Mu CY, Huang JA, Chen Y, et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28(3):682–688.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361–370.
   PubMed Web of Science ®Google Scholar
• Walker LSK, Sansom DM. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol. 2015;36(2):63–70.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Flies DB, Marjon NA, et al. CTLA-4 Blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015;3(11):1257–1268.
   PubMed Web of Science ®Google Scholar
• Hida K, Hida Y, Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci. 2008;99(3):459–466.
   PubMed Web of Science ®Google Scholar
• Chouaib S, Kieda C, Benlalam H, et al. Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol. 2010;30(6):529–545.
   PubMed Web of Science ®Google Scholar
• Lichtenberger BM, Tan PK, Niederleithner H, et al. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell. 2010;140(2):268–279.
   PubMed Web of Science ®Google Scholar
• Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22.
   PubMed Web of Science ®Google Scholar
• Witz IP. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Rev. 2008;27(1):19–30.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. The Oncologist. 2015;20(6):660–673.
   PubMed Web of Science ®Google Scholar
• Seguin L, Desgrosellier JS, Weis SM, et al. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015;25(4):234–240.
   PubMed Web of Science ®Google Scholar
• Cheresh DA, Stupack DG. Integrin-mediated death: an explanation of the integrin-knockout phenotype?. Nat Med. 2002;8(3):193–194.
   PubMed Web of Science ®Google Scholar
• Rapisarda A, Melillo G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res. 2012;114:237–267.
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 2013;153(1):13–19.
   PubMed Web of Science ®Google Scholar
• Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871–882.
   PubMed Web of Science ®Google Scholar
• Laubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol. 2010;20(3):169–177.
   PubMed Web of Science ®Google Scholar
• Laubli H, Spanaus KS, Borsig L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood. 2009;114(20):4583–4591.
   PubMed Web of Science ®Google Scholar
• Nasti TH, Bullard DC, Yusuf N. P-selectin enhances growth and metastasis of mouse mammary tumors by promoting regulatory T cell infiltration into the tumors. Life Sci. 2015;131:11–18.
   PubMed Web of Science ®Google Scholar
• Estanqueiro M, Amaral MH, Conceicao J, et al. Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloid Surface B. 2015;126:631–648.
   PubMed Web of Science ®Google Scholar
• Swartz MA, Iida N, Roberts EW, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res. 2012;72(10):2473–2480.
   PubMed Web of Science ®Google Scholar
• Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Controlled Release. 2010;148(2):135–146.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21(5):634–642.
   PubMed Web of Science ®Google Scholar
• Chuk MK, Chang JT, Theoret MR, et al. FDA approval summary: accelerated approval of pembrolizumab for second-line treatment of metastatic melanoma. Clin Cancer Res. 2017;23(19):5666–5670.
   PubMed Web of Science ®Google Scholar
• Casak SJ, Fashoyin-Aje I, Lemery SJ, et al. FDA approval summary: ramucirumab for gastric cancer. Clin Cancer Res. 2015;21(15):3372–3376.
   PubMed Web of Science ®Google Scholar
• Casak SJ, Lemery SJ, Chung J, et al. FDA’s approval of the first biosimilar to bevacizumab. Clin Cancer Res. 2018;24(18):4365–4370.
   PubMed Web of Science ®Google Scholar
• Ettrich TJ, Seufferlein T. Regorafenib. Recent Results Cancer Res. 2018;211:45–56.
   PubMedGoogle Scholar
• Wu P, Nielsen TE, Clausen MH. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discov Today. 2016;21(1):5–10.
   PubMed Web of Science ®Google Scholar
• Tan FH, Putoczki TL, Stylli SS, et al. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. Oncotargets Ther. 2019;12:635–645.
   PubMed Web of Science ®Google Scholar
• de Claro RA, McGinn KM, Verdun N, et al. FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2015;21(16):3586–3590.
   PubMed Web of Science ®Google Scholar
• Padda A, Schiopu E, Sovich J, et al. Ipilimumab induced digital vasculitis. J Immunother Cancer. 2018;6:120.
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Habra MA. Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev. 2016;42:47–55.
   PubMed Web of Science ®Google Scholar
• Pisano SG, Hoffman SE, Legasto CS, et al. Effect of acid-suppressive strategies on pazopanib efficacy in patients with soft-tissue sarcoma. Clin Transl Sci. 2019;12(5):529–533.
   PubMed Web of Science ®Google Scholar
• Opneja A, Cioffi G, Alahmadi A, et al. The impact of sorafenib on the treatment and survival of advanced hepatocellular carcinoma (HCC): analysis of the National Cancer Database (NCDB) from 2004 to 2014. J Clin Oncol. 2019;37(15).
   Google Scholar
• Blumenthal GM, Cortazar P, Zhang JJ, et al. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist. 2012;17(8):1108–1113.
   PubMed Web of Science ®Google Scholar
• Parekh H, Griswold J, Rini B. Axitinib for the treatment of metastatic renal cell carcinoma. Future Oncol. 2016;12(3):303–311.
   PubMed Web of Science ®Google Scholar
• Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315(3):971–979.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007;9(2):115–119.
   PubMedGoogle Scholar
• Chellappan DK, Chellian J, Ng ZY, et al. The role of pazopanib on tumour angiogenesis and in the management of cancers: a review. Biomed Pharmacother. 2017;96:768–781.
   PubMed Web of Science ®Google Scholar
• Dong Y, Jia L, Wang X, et al. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells. Int J Oncol. 2011;38(2):555–569.
   PubMed Web of Science ®Google Scholar
• Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemotherapy Research and Practice. 2014;2014(357027):1–9.
   Google Scholar
• Ogata K, Kimura A, Nakazawa N, et al. Long-term imatinib treatment for patients with unresectable or recurrent gastrointestinal stromal tumors. Digestion. 2018;97(1):20–25.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Int. J Clin Oncol. 2013;131(1):88–94.
   Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
   PubMed Web of Science ®Google Scholar
• Varughese T, Taur Y, Cohen N, et al. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. Clin Infect Dis. 2018;67(5):687–692.
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317–327.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Bravo-San Pedro JM, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014;5(24):12472–12508.
   PubMed Web of Science ®Google Scholar
• Hofheinz RD, Al-Batran SE, Hartmann F, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Oncol Res Treat. 2003;26(1):44–48.
   Google Scholar
• Baird SK, Allan L, Renner C, et al. Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways. Clin Exp Metastasis. 2015;32(5):507–516.
   PubMed Web of Science ®Google Scholar
• Hintz HM, Cowan AE, Shapovalova M, et al. Development of a cross-reactive monoclonal antibody for detecting the tumor stroma. Bioconjugate Chem. 2019;30(5):1466–1476.
   PubMed Web of Science ®Google Scholar
• Kazazi-Hyseni F, Beijnen JH, Schellens J. Bevacizumab. Oncologist. 2010;15(8):819–825.
   PubMed Web of Science ®Google Scholar
• Roma-Rodrigues C, Mendes R, Baptista PV, et al. Targeting tumor microenvironment for cancer therapy. ‎Int J Mol Sci. 2019;20(4):840.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400.
   PubMed Web of Science ®Google Scholar
• Vuletic I, Zhou K, Li H, et al. Validation of bevacizumab therapy effect on colon cancer subtypes by using whole body imaging in mice. Mol Imaging Biol. 2017;19(6):847–856.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol. 2015;11(9):1307–1326.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–265.
   PubMed Web of Science ®Google Scholar
• Tehrani RM, Verdi J, Noureddini M, et al. Mesenchymal stem cells: a new platform for targeting suicide genes in cancer. J Cell Physiol. 2018;233(5):3831–3845.
   PubMed Web of Science ®Google Scholar
• Bobbin ML, Rossi JJ. RNA Interference (RNAi)-based therapeutics: delivering on the promise? Annu Rev Pharmacol Toxicol. 2016;56(1):103–122.
   PubMedGoogle Scholar
• Fujita Y, Kuwano K, Ochiya T. Development of small RNA delivery systems for lung cancer therapy. IJMS. 2015;16(12):5254–5270.
   Google Scholar
• Guo W, Chen W, Yu W, et al. Small interfering RNA-based molecular therapy of cancers. Chin J Cancer. 2013;32(9):488–493.
   PubMedGoogle Scholar
• Felnerova D, Viret JF, Gluck R, et al. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol. 2004;15(6):518–529.
   PubMed Web of Science ®Google Scholar
• Asadi N, Davaran S, Panahi Y, et al. Application of nanostructured drug delivery systems in immunotherapy of cancer: a review. Artif Cells Nanomed Biotechnol. 2017;45(1):18–23.
   PubMed Web of Science ®Google Scholar
• Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst. 2012;104(8):599–613.
   PubMed Web of Science ®Google Scholar
• Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res. 2007;13(13):3776–3782.
   PubMed Web of Science ®Google Scholar
• Madan RA, Arlen PM, Mohebtash M, et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18(7):1001–1011.
   PubMed Web of Science ®Google Scholar
• Chen B, Wang Z, Sun J, et al. A tenascin C targeted nanoliposome with navitoclax for specifically eradicating of cancer-associated fibroblasts. Nanomed Nanotechnol Biol Med. 2016;12(1):131–141.
   PubMed Web of Science ®Google Scholar
• Bianchini F, De Santis A, Portioli E, et al. Integrin-targeted AmpRGD sunitinib liposomes as integrated antiangiogenic tools. Nanomed Nanotechnol Biol Med. 2019;18:135–145.
   PubMed Web of Science ®Google Scholar
• Han QJ, Jia XQ, Qian YX, et al. Peptide functionalized targeting liposomes: for nanoscale drug delivery towards angiogenesis. J Mater Chem B. 2016;4(44):7087–7091.
   PubMed Web of Science ®Google Scholar
• Li C, Lai C, Qiu Q, et al. Dual-ligand modification of pegylated liposomes used for targeted doxorubicin delivery to enhance anticancer efficacy. AAPS PharmSciTech. 2019;1520(5):188.
   PubMed Web of Science ®Google Scholar
• Du Y, Liang X, Li Y, et al. Nuclear and fluorescent labeled PD-1-Liposome-DOX-(64)Cu/IRDye800CW allows improved breast tumor targeted imaging and therapy. Mol Pharmaceutics. 2017;14(11):3978–3986.
   PubMed Web of Science ®Google Scholar
• Chen Y, Feng S, Liu W, et al. Vitamin E succinate-grafted-chitosan oligosaccharide/RGD-conjugated tpgs mixed micelles loaded with paclitaxel for U87MG tumor therapy. Mol Pharmaceutics. 2017;14(4):1190–1203.
   PubMed Web of Science ®Google Scholar
• Ji T, Ding Y, Zhao Y, et al. Peptide assembly integration of fibroblast-targeting and cell-penetration features for enhanced antitumor drug delivery. Adv Mater. 2015;27(11):1865–1873.
   PubMed Web of Science ®Google Scholar
• Ji T, Zhao Y, Ding Y, et al. Transformable peptide nanocarriers for expeditious drug release and effective cancer therapy via cancer-associated fibroblast activation. Angew Chem Int Ed. 2016;55(3):1050–1055.
   PubMed Web of Science ®Google Scholar
• Meng Z, Yang X, Hu D, et al. Replacing heme with paclitaxel to prepare drug-loaded globin nanoassembles for CD163 targeting. J Pharm Sci. 2015;104(3):1045–1055.
   PubMed Web of Science ®Google Scholar
• Zhen Z, Tang W, Wang M, et al. Protein nanocage mediated fibroblast-activation protein targeted photoimmunotherapy to enhance cytotoxic T cell infiltration and tumor control. Nano Lett. 2017;17(2):862–869.
   PubMed Web of Science ®Google Scholar
• Wang P, Wang H, Huang Q, et al. Exosomes from M1-polarized macrophages enhance paclitaxel antitumor activity by activating macrophages-mediated inflammation. Theranostics. 2019;9(6):1714–1727.
   PubMed Web of Science ®Google Scholar
• Rejeeth C, Vivek R, NipunBabu V, et al. Cancer nanomedicine: from PDGF targeted drug delivery. Med Chem Commun. 2017;8(11):2055–2059.
   Google Scholar
• Zang X, Zhang X, Hu H, et al. Targeted delivery of zoledronate to tumor-associated macrophages for cancer immunotherapy. Mol Pharmaceutics. 2019;16(5):2249–2258.
   PubMed Web of Science ®Google Scholar
• Li X, Wu M, Pan L, et al. Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor. Int J Nanomedicine. 2016;11:93–105.
   PubMed Web of Science ®Google Scholar
• Hosseini M, Haji-Fatahaliha M, Jadidi-Niaragh F, et al. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. Artif Cells Nanomed Biotechnol. 2016;44(4):1051–1061.
   PubMed Web of Science ®Google Scholar
• Guo X, Wei X, Chen Z, et al. Multifunctional nanoplatforms for subcellular delivery of drugs in cancer therapy. Prog Mater Sci. 2020;107:100599.
   Web of Science ®Google Scholar
• Guo X, Wang L, Duval K, et al. Dimeric drug polymeric micelles with acid-active tumor targeting and FRET-traceable drug release. Adv Mater. 2018;30(3):1705436.
   Web of Science ®Google Scholar
• Liu D, Yang F, Xiong F, et al. The smart drug delivery system and its clinical potential. Theranostics. 2016;6(9):1306–1323.
   PubMed Web of Science ®Google Scholar
• Muthu MS, Feng SS. Theranostic liposomes for cancer diagnosis and treatment: current development and pre-clinical success. Expert Opin Drug Del. 2013;10(2):151–155.
   PubMed Web of Science ®Google Scholar
• Gao W, Hu CM, Fang RH, et al. Liposome-like nanostructures for drug delivery. J Mater Chem B. 2013;1(48):6569e85.
   Web of Science ®Google Scholar
• Sharma G, Anabousi S, Ehrhardt C, et al. Liposomes as targeted drug delivery systems in the treatment of breast cancer. J Drug Targeting. 2006;14(5):301–310.
   PubMed Web of Science ®Google Scholar
• Shahin M, Safaei-Nikouei N, Lavasanifar A. Polymeric micelles for pH-responsive delivery of cisplatin. J Drug Targeting. 2014;22(7):629–637.
   PubMed Web of Science ®Google Scholar
• Afsharzadeh M, Hashemi M, Mokhtarzadeh A, et al. Recent advances in co-delivery systems based on polymeric nanoparticle for cancer treatment. Artif Cells Nanomed Biotechnol. 2018;46(6):1095–1110.
   PubMed Web of Science ®Google Scholar
• An FF, Zhang XH. Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery. Theranostics. 2017;7(15):3667–3689.
   PubMed Web of Science ®Google Scholar
• Lohcharoenkal W, Wang L, Chen YC, et al. Protein nanoparticles as drug delivery carriers for cancer therapy. BioMed Res Int. 2014;2014:1–12.
   Web of Science ®Google Scholar
• Yin K, Wang SH, Zhao RC. Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm. Biomark Res. 2019;7(1):42.
   Google Scholar
• Tian T, Zhang HX, He CP, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials. 2018;150:137–149.
   PubMed Web of Science ®Google Scholar
• Liong M, Lu J, Kovochich M, et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. Acs Nano. 2008;2(5):889–896.
   PubMed Web of Science ®Google Scholar
• Jung HS, Han J, Lee JH, et al. Enhanced NIR radiation-triggered hyperthermia by mitochondrial targeting. J Am Chem Soc. 2015;137(8):3017–3023.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li D, Sun H, et al. Quantitative control of active targeting of nanocarriers to tumor cells through optimization of folate ligand density. Biomaterials. 2014;35(27):8015–8027.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wei G, Zhang X, et al. Multistage targeting strategy using magnetic composite nanoparticles for synergism of photothermal therapy and chemotherapy. Small. 2018;14(12):e1702994.
   PubMed Web of Science ®Google Scholar
• Huang HC, Barua S, Sharma G, et al. Inorganic nanoparticles for cancer imaging and therapy. J Con Release. 2011;155(3):344–357.
   PubMed Web of Science ®Google Scholar
• Li W, Cao Z, Liu R, et al. AuNPs as an important inorganic nanoparticle applied in drug carrier systems. Artif Cells Nanomed Biotechnol. 2019;47(1):4222–4233.
   PubMed Web of Science ®Google Scholar